What is claimed is:

1. A complex granule formulation comprising:

(a) a first granular part comprising levocetirizine or a pharmaceutically acceptable salt thereof, cyclodextrin or a derivative thereof, and an alkalinizing agent; and

(b) a second granular part comprising montelukast or a pharmaceutically acceptable salt thereof, cyclodextrin or a derivative thereof, and an alkalinizing agent,

wherein the cyclodextrin or its derivative is β-cyclodextrin or hydroxypropyl β-cyclodextrin.

2. The complex granule formulation of claim 1, wherein the cyclodextrin or its derivative is contained in an amount of 3 to 7 wt % based on the total weight of each granular part.

3. The complex granule formulation of claim 1, wherein the alkalinizing agent is selected from the group consisting of meglumine, sodium bicarbonate, sodium carbonate monohydrate, ammonia water, sodium citrate, dried sodium carbonate, and a mixture thereof.

4. The complex granule formulation of claim 1, wherein the alkalinizing agent is contained in an amount of 0.2 to 0.6 wt % based on the total weight of each granular part.

5. The complex granule formulation of claim 1, wherein each of the first and the second granular parts further comprises a pharmaceutically acceptable additive.

6. The complex granule formulation of claim 5, wherein the pharmaceutically acceptable additive is selected from the group consisting of a diluent, a sweetener, a flavor, a colorant, a binder, and a mixture thereof.

7. The complex granule formulation of claim 1, for use in the treatment of allergic rhinitis or asthma.